afimkibart vs tulisokibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

afimkibart

Developed by Roche and partners

Phase 3 in Ulcerative Colitismonoclonal antibody
Partial signal

NCT04090411 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 study (N=246) in moderate-to-severe ulcerative colitis, with Week 14 clinical remission on the Mayo score as the primary endpoint. Although remission rates were numerically higher in all afimkibart dose groups (25.5%, 23.3%, 23.9%) than placebo (11.6%), the differences were not statistically significant (one-sided p-values 0.055–0.082; 90% confidence intervals crossed zero), so the primary efficacy comparison was not met. The well-controlled design is real evidence, but because the primary endpoint was missed, the trial does not rise to strong evidence of benefit.

Next expected readout: January 2027 · NCT06589986 (registry estimate)

Reported efficacy

Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14; Induction Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With Serious Adverse Events (SAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Chronic Period: Number of Participants With TEAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With SAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)): Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) (missed)

Result source: NCT04090411

tulisokibart

Developed by Merck & Co.

Phase 3 in Ulcerative Colitismonoclonal antibody (humanized)
Reliable signal

NCT06052059 · Phase 3 · active, not recruiting

First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2037 · NCT06651281 (registry estimate)

Reported efficacy

Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)

Result source: NCT06052059

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointafimkibarttulisokibart
Clinical remission (induction)23.9% vs 11.6%+12.3 vs placebo450 mg · wk 14 · n 88NCT04090411
2 other results
  • 23.3% vs 11.6% 150 mg · wk 14 · n 60 · Phase 2 · primary NCT04090411
  • 25.5% vs 11.6% 50 mg · wk 14 · n 47 · Phase 2 · primary NCT04090411
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Clinical remission (maintenance)—Trial running · NCT06589986—Trial running · NCT06052059
Clinical response (induction)—Trial running · NCT0658998666.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Endoscopic improvement (induction)40.9% vs 18.6%+22.3 vs placebo450 mg · n 88NCT04090411
8 other results
  • 36% vs 18.6% 450 mg (Induction) to 50 mg (Chronic) · n 25 · Phase 2 · secondary NCT04090411
  • 37.5% vs 18.6% 450 mg (Induction) to 150 mg (Chronic) · n 24 · Phase 2 · secondary NCT04090411
  • 50% vs 18.6% 450 mg (Induction) to 450 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 38.3% vs 18.6% 150 mg · n 60 · Phase 2 · secondary NCT04090411
  • 37% vs 18.6% 150 mg (Induction) to 50 mg (Chronic) · n 27 · Phase 2 · secondary NCT04090411
  • 39.3% vs 18.6% 150 mg (Induction) to 150 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 40.4% vs 18.6% 50 mg · n 47 · Phase 2 · secondary NCT04090411
  • 38.1% vs 18.6% 50 mg (Induction) to 50 mg (Chronic) · n 42 · Phase 2 · secondary NCT04090411
36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Corticosteroid-free remission (maintenance)—Trial running · NCT06589986—Trial running · NCT06052059

Clinical remission (induction)

afimkibart
23.9% vs 11.6%+12.3 vs placebo450 mg · wk 14 · n 88NCT04090411
2 other results
  • 23.3% vs 11.6% 150 mg · wk 14 · n 60 · Phase 2 · primary NCT04090411
  • 25.5% vs 11.6% 50 mg · wk 14 · n 47 · Phase 2 · primary NCT04090411
tulisokibart
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Clinical remission (maintenance)

afimkibart
—Trial running · NCT06589986
tulisokibart
—Trial running · NCT06052059

Clinical response (induction)

afimkibart
—Trial running · NCT06589986
tulisokibart
66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Endoscopic improvement (induction)

afimkibart
40.9% vs 18.6%+22.3 vs placebo450 mg · n 88NCT04090411
8 other results
  • 36% vs 18.6% 450 mg (Induction) to 50 mg (Chronic) · n 25 · Phase 2 · secondary NCT04090411
  • 37.5% vs 18.6% 450 mg (Induction) to 150 mg (Chronic) · n 24 · Phase 2 · secondary NCT04090411
  • 50% vs 18.6% 450 mg (Induction) to 450 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 38.3% vs 18.6% 150 mg · n 60 · Phase 2 · secondary NCT04090411
  • 37% vs 18.6% 150 mg (Induction) to 50 mg (Chronic) · n 27 · Phase 2 · secondary NCT04090411
  • 39.3% vs 18.6% 150 mg (Induction) to 150 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 40.4% vs 18.6% 50 mg · n 47 · Phase 2 · secondary NCT04090411
  • 38.1% vs 18.6% 50 mg (Induction) to 50 mg (Chronic) · n 42 · Phase 2 · secondary NCT04090411
tulisokibart
36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Corticosteroid-free remission (maintenance)

afimkibart
—Trial running · NCT06589986
tulisokibart
—Trial running · NCT06052059
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. afimkibart: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricafimkibarttulisokibart
Dropout rate
8.7%450 mga
NCT04090411 · Phase 2
show 9 more results
—450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6.5%150 mg
NCT04090411 · Phase 2
—150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2.1%50 mg
NCT04090411 · Phase 2
—50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
n/a: no completion milestoneCohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
1.1%450 mga
NCT04090411 · Phase 2
show 9 more results
—450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
1.6%150 mg
NCT04090411 · Phase 2
—150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2.1%50 mg
NCT04090411 · Phase 2
—50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
0%Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
4.4%450 mga
NCT04090411 · Phase 2
show 9 more results
3.8%450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
13.8%450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
7.7%450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
1.6%150 mg
NCT04090411 · Phase 2
0%150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
3.7%150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6.4%50 mg
NCT04090411 · Phase 2
10.9%50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
1.1%All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
—Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
450 mga
headache 9.9% (placebo 2.2%)
fatigue 5.5% (placebo 0%)
pyrexia 5.5% (placebo 2.2%)
NCT04090411 · Phase 2
show 9 more results
450 mg (Induction) to 150 mg (Chronic)
anaemia 11.5% (placebo 8.9%)
colitis ulcerative 11.5% (placebo 0%)
sars-cov-2 test positive 11.5% (placebo 0%)
NCT04090411 · Phase 2
450 mg (Induction) to 450 mg (Chronic)
blood creatine phosphokinase increased 10.3% (placebo 4.4%)
anaemia 6.9% (placebo 8.9%)
covid-19 6.9% (placebo 0%)
NCT04090411 · Phase 2
450 mg (Induction) to 50 mg (Chronic)
colitis ulcerative 23.1% (placebo 0%)
sars-cov-2 test positive 15.4% (placebo 0%)
anaemia 11.5% (placebo 8.9%)
NCT04090411 · Phase 2
150 mg
anaemia 8.1% (placebo 8.9%)
injection site reaction 4.8% (placebo 2.2%)
headache 3.2% (placebo 2.2%)
NCT04090411 · Phase 2
150 mg (Induction) to 150 mg (Chronic)
nausea 10% (placebo 2.2%)
oropharyngeal pain 10% (placebo 2.2%)
sars-cov-2 test positive 10% (placebo 0%)
NCT04090411 · Phase 2
150 mg (Induction) to 50 mg (Chronic)
sars-cov-2 test positive 18.5% (placebo 0%)
colitis ulcerative 14.8% (placebo 0%)
injection site reaction 11.1% (placebo 2.2%)
NCT04090411 · Phase 2
50 mg
nausea 6.4% (placebo 2.2%)
urinary tract infection 6.4% (placebo 0%)
anaemia 4.3% (placebo 8.9%)
NCT04090411 · Phase 2
50 mg (Induction) to 50 mg (Chronic)
colitis ulcerative 17.4% (placebo 0%)
anaemia 8.7% (placebo 8.9%)
blood creatine phosphokinase increased 6.5% (placebo 4.4%)
NCT04090411 · Phase 2
500 mg IV
arthralgia 12%
colitis ulcerative 10%
abdominal pain 6%
NCT02840721 · Phase 2 · registry result, not featured evidence
covid-19 5.6% (placebo 4.5%)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

afimkibart

Clinical Remission 23.9% (n=88) vs 11.6% (n=43) placebo @ 14wk450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 2 more results
23.3% (n=60) vs 11.6% (n=43) placebo @ 14wk150 mg
NCT04090411 · Phase 2
25.5% (n=47) vs 11.6% (n=43) placebo @ 14wk50 mg
NCT04090411 · Phase 2
Modified Remission 1 14.8% (n=88) vs 7% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
20.8% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
17.9% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
13.3% (n=60) vs 7% (n=43) placebo150 mg
NCT04090411 · Phase 2
22.2% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
23.1% (n=26) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
14.9% (n=47) vs 7% (n=43) placebo50 mg
NCT04090411 · Phase 2
16.7% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Modified Remission 2 31.8% (n=88) vs 11.6% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
28% (n=25) vs 11.6% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
33.3% (n=24) vs 11.6% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
35.7% (n=28) vs 11.6% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
35% (n=60) vs 11.6% (n=43) placebo150 mg
NCT04090411 · Phase 2
33.3% (n=27) vs 11.6% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
38.5% (n=26) vs 11.6% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
29.8% (n=47) vs 11.6% (n=43) placebo50 mg
NCT04090411 · Phase 2
31% (n=42) vs 11.6% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Improvement 40.9% (n=88) vs 18.6% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
36% (n=25) vs 18.6% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
37.5% (n=24) vs 18.6% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
50% (n=28) vs 18.6% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
38.3% (n=60) vs 18.6% (n=43) placebo150 mg
NCT04090411 · Phase 2
37% (n=27) vs 18.6% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
39.3% (n=28) vs 18.6% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
40.4% (n=47) vs 18.6% (n=43) placebo50 mg
NCT04090411 · Phase 2
38.1% (n=42) vs 18.6% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Remission 10.2% (n=88) vs 7% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
8.3% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
21.4% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
10% (n=60) vs 7% (n=43) placebo150 mg
NCT04090411 · Phase 2
7.4% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
7.1% (n=28) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
19.1% (n=47) vs 7% (n=43) placebo50 mg
NCT04090411 · Phase 2
11.9% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Clinical Remission 24% (n=25) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
25% (n=24) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
39.3% (n=28) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
29.6% (n=27) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
34.6% (n=26) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
31% (n=42) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Clinical Remission 28.6% (n=7) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
50% (n=6) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
85.7% (n=7) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
50% (n=6) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
62.5% (n=8) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
50% (n=12) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Modified Remission 1 25% (n=4) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
0% (n=3) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
80% (n=5) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
40% (n=5) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
66.7% (n=3) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
28.6% (n=7) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Modified Remission 2 33.3% (n=9) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
60% (n=10) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
75% (n=8) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
70% (n=10) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
54.5% (n=11) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
42.9% (n=14) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Endoscopic Improvement 46.2% (n=13) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
63.6% (n=11) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
80% (n=10) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
80% (n=10) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
61.5% (n=13) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
47.4% (n=19) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Endoscopic Remission 66.7% (n=3) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
50% (n=2) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
66.7% (n=3) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
50% (n=2) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
25% (n=4) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
22.2% (n=9) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Improvement 38.2% (n=45) @ 14wk500 mg IV
responder rate · % of participants
No placebo or comparator arm
NCT02840721 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

tulisokibart

Clinical Remission 26.5% (n=68) vs 1.5% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
31.6% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Endoscopic Improvement 36.8% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
36.8% (n=38) vs 18.9% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Clinical Response 66.2% (n=68) vs 22.4% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.3% (n=38) vs 32.4% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Symptomatic Remission 19.1% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
21.1% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic Improvement 46.2% (n=65) vs 17.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.6% (n=36) vs 26.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-Endoscopic Mucosal Improvement 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-endoscopic Mucosal Healing 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
IBDQ 82.4% (n=68) vs 49.3% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
76.3% (n=38) vs 56.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: afimkibart's landscape · tulisokibart's landscape